TG Therapeutics announces SPA agreement with FDA for its first phase 3 clinical trial
TG Therapeutics announced an agreement with the FDA regarding a Special Protocol Assessment on the design, endpoints and statistical analysis approach of a Phase 3 clinical trial for TG-1101 (ublituximab), its glycoengineered anti-CD20 monoclonal antibody, in combination with Imbruvica® (ibrutinib). September 15, 2014